Analyst Price Target is $6.00
▲ +837.50% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for BioAtla in the last 3 months. The average price target is $6.00, with a high forecast of $7.00 and a low forecast of $5.00. The average price target represents a 837.50% upside from the last price of $0.64.
Current Consensus is
Moderate Buy
The current consensus among 2 contributing investment analysts is to moderate buy stock in BioAtla. This rating has held steady since October 2024, when it changed from a Buy consensus rating.
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.
Read More
